AVIDITY BIOSCIENCES
Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more eff... ectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has development efforts focused on immune and other cell types.
AVIDITY BIOSCIENCES
Industry:
Biotechnology Health Care Life Science Pharmaceutical Therapeutics
Founded:
2013-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.aviditybiosciences.com
Total Employee:
251+
Status:
Active
Contact:
858-401-7900
Email Addresses:
[email protected]
Total Funding:
1.21 B USD
Similar Organizations
Abzena
Abzena provides complementary services to organizations involved in the development of bio-pharmaceuticals.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Pyxis Biologix
Pyxis Biologix is a biotech company that develops topical pharmaceutical peptide serum for skin disorders.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Farallon Capital Management
Farallon Capital Management investment in Post-IPO Equity - Avidity Biosciences
Janus Henderson Investors
Janus Henderson Investors investment in Post-IPO Equity - Avidity Biosciences
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Avidity Biosciences
Wellington Management
Wellington Management investment in Post-IPO Equity - Avidity Biosciences
Casdin Capital
Casdin Capital investment in Post-IPO Equity - Avidity Biosciences
Boxer Capital
Boxer Capital investment in Post-IPO Equity - Avidity Biosciences
Adage Capital Management
Adage Capital Management investment in Post-IPO Equity - Avidity Biosciences
RTW Investments
RTW Investments investment in Post-IPO Equity - Avidity Biosciences
Perceptive Advisors
Perceptive Advisors investment in Series C - Avidity Biosciences
Takeda Ventures
Takeda Ventures investment in Series C - Avidity Biosciences
Key Employee Changes
Official Site Inspections
http://www.aviditybiosciences.com Semrush global rank: 1.47 M Semrush visits lastest month: 16.82 K
- Host name: 129.177.197.104.bc.googleusercontent.com
- IP address: 104.197.177.129
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Avidity Biosciences"
Overview - Avidity Biosciences
Our Broad and Disruptive Platform We are delivering a new class of RNA therapeutics – Antibody Oligonucleotide Conjugates (AOCs™). AOCs are designed to combine the specificity of monoclonal antibodies with the …See details»
About - Avidity Biosciences
Our vision is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics. We’re utilizing our proprietary AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of …See details»
Avidity Biosciences, Inc. | LinkedIn
Avidity Biosciences, Inc. | 19,176 followers on LinkedIn. DELIVERING ON OUR VISION Our vision is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics. We’re ...See details»
Avidity Biosciences - Crunchbase Company Profile
Avidity Biosciences reported impressive financial results, leading to a record high in its stock price. The company successfully raised $400 million through an oversubscribed private placement.See details»
Avidity Biosciences, Inc. (RNA)
See the company profile for Avidity Biosciences, Inc. (RNA) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
January 2021 Avidity Corporate Presentation
BUILDING an extraordinary biotech organization to bring our AOC therapies to patients. ESTABLISHING the right teams and growing together in service of patients and their families. …See details»
Avidity Biosciences - VentureRadar
Similar Companies: Avidity NanoMedicines USA Privately Held Avidity NanoMedicines is pioneering a new class of therapeutics, antibody-siRNA complexes (ARCs?), which employ …See details»
Avidity Biosciences - Craft
Oct 29, 2024 Avidity Biosciences is a biotech company developing oligonucleotide-based therapies called antibody oligonucleotide conjugates (AOC). The company utilizes its AOC …See details»
Management - Avidity Biosciences
At Avidity Biosciences, our commitment to rigorous and innovative science is matched only by our passion to see people’s lives changed. We consistently challenge ourselves to Be AVID – Agile, Visionary, Integrated and Diverse.See details»
Avidity Biosciences Announces New Precision Cardiology …
Nov 12, 2024 Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates …See details»
Avidity Biosciences Announces Expansion of Cardiovascular …
Nov 28, 2023 For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X. …See details»
Avidity Biosciences - Products, Competitors, Financials, Employees ...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 21, 2024. News provided by Share this article Share toX SAN DIEGO, Nov. 21, 2024 …See details»
Avidity Biosciences Announces Expansion of Cardiovascular …
Nov 28, 2023 Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates …See details»
Overview - Avidity Biosciences
Driven by our mission to profoundly improve the lives of people affected by serious diseases, our proprietary AOC™ platform expands the ability to address targets and diseases previously …See details»
Avidity Biosciences Announces 2024 Corporate Priorities and …
Jan 5, 2024 Avidity plans to initiate global Phase 3 HARBOR™ trial of AOC 1001 for DM1 mid-2024 . Company to report data from all three ongoing clinical programs in 2024 -- AOC 1001 …See details»
Avidity Biosciences to Participate in Upcoming Investor Conference
3 days ago Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates …See details»
Careers - Avidity Biosciences
Characterized by enthusiasm and vigorous pursuit Value Behavior Examples Agile Entrepreneurial Spirit, Adaptability(growth,resilient, intentional, fast-paced learning, sense of urgency, commit …See details»
Avidity Biosciences Announces New Precision Cardiology …
Nov 12, 2024 heartbeats), sudden cardiac arrest and heart failure. There are no FDA-approved disease-modifying therapies for PLN cardiomyopathy, and current standard of care focuses on …See details»
Pipeline - Avidity Biosciences
We are advancing and expanding our innovative AOC pipeline to offer treatment options for patients and their families across a wide range of therapeutic areas.See details»